biomed devic servic
multipl growth driver intact guid
street rais pt buy
consist pre-announc deliv excel beat
street estim reiter guid top-lin growth adj
ep y/i remain one top pick given
domin leadership highli attract nascent next-gen sequenc market
mani growth driver ahead rais estim pt
guid us/th street expect rev come
ahead prior q/q
expect see big custom consum stock order like one
order suspect grail compani expect seq instrument rev
q/q season instrument grew y/i y/i
novaseq guid transpar initi novaseq guid
instrument y/i midpoint estim view
solid guid achiev given roll-out flow cell later may
convert lower volum hiseq user sooner addit on-going roll-out flow
cell longer provid quarterli placement rather per year
may view disappoint understand rational given possibl
hint demand elast sequenc consum similar robust
growth ancestri array growth point price reduct
dtc kit low help drive number folk
genotyp consum market nearli tripl price drop
dtc market result surg volum bet price/run drop
novaseq like unlock meaning sequenc run
beat driven consum qualiti beat revenu y/
beat street initi y/i growth sequenc
consum driven novaseq servic revenu
y/i beat adj ep beat street
adj gm q/q beat adj om beat
novaseq deliv novaseq placement basic match
instal manag suspend quarterli disclosur
novaseq placement instead disclos number end year
order came custom new sequenc bench-top system
hiseq custom taken least one novaseq driven launch howev
manag think roll-out like phase multipl year though
guid ahead forecast suggest visibl funnel
confid view
guide/model reiter revenue guid growth y/i
adj ep includ lift tax reform top line
rais rev
adj ep rais rev
adj ep street
price close busi januari
domin global leader next gener
sequenc instrument consum
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
iseq beta unit field perform well order come
new iseq formerli known firefli though broader launch like occur
iseq expect expand low end
sequenc market believ hope lure lab new sequenc
eventu move valu chain larger equip
expect materi revenu iseq
america pace growth geograph major geograph region revenu
america grew y/i follow emea y/i asia pacif y/
china grew shipment y/i japan remain laggard
research novaseq convers schedul may
good thing durat growth novaseq adopt like
continu good pace least like longer view
 custom instal least one novaseq fulli convert
fleet instrument novaseq manag cite rational
cadenc clinic translat research activ end result
novaseq like multi-year adopt cycl least like
end longer view depend whether follow
anoth blockbust launch perhap certainli research
institut may need wait end make addit capit
purchas fiscal year
flow cell launch revenu beat part function initi
roll-out flow cell even better expect manag eye roll-out
flow cell complet intern valid expect roll
end think launch flow cell may encourag
hiseq custom migrat novaseq sinc flow cell deliv
fastest run time faster deliv run hour
like novaseq flow cell configur flow cell novaseq
provid lower consum cost rel hiseq manag
believ lower sequenc consum price driver sequenc
new custom novaseq manag state
one-third novaseq order either new sequenc previous
benchtop custom new-to-illumina custom academ translat
lab clinic test whole exom sequenc we whole genom
sequenc wg convert desktop-onli we wg circul
tumor dna liquid biopsi work methyl analysi rna project
hiseq hiseqx consist think place
hiseq instrument highli suggest us new placement
instrument like favor novaseq indic place
hand hiseq like estim given
attract econom novaseq upcom launch flow cell think
new placement cycel hiseq also like come end good news
hiseq consum increas q/q howev natur expect
consum declin favor rise novaseq consum
clinic oncolog test shipment grew y/i expect
segment continu solid growth nipt also continu grow though
manag provid number clearli grow adopt average-risk nipt
mark materi growth driver next sever year whenev
aet decid cover average-risk women make birth year
us
nextseqdx instrument seem get lost shuffl bit mid-novemb
launch nextseq second fda-clear system follow
miseqdx system flexibl run either diagnost mode research
mode expect launch number clinic applic oncolog
reproduct health system time earli custom look use system
liquid biopsi test use non-smal cell lung cancer nsclc addit
buy unchang target price januari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
